| Basics |
CytomX Therapeutics, Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is engaged in developing antibody therapeutics based on probody technology platform.
|
| IPO Date: |
October 8, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$395.44M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.25 | 2.97%
|
| Avg Daily Range (30 D): |
$0.12 | 7.02%
|
| Avg Daily Range (90 D): |
$0.06 | 5.34%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.79M |
| Avg Daily Volume (30 D): |
7.1M |
| Avg Daily Volume (90 D): |
3.44M |
| Trade Size |
| Avg Trade Size (Sh.): |
194 |
| Avg Trade Size (Sh.) (30 D): |
391 |
| Avg Trade Size (Sh.) (90 D): |
405 |
| Institutional Trades |
| Total Inst.Trades: |
832 |
| Avg Inst. Trade: |
$1.44M |
| Avg Inst. Trade (30 D): |
$1.15M |
| Avg Inst. Trade (90 D): |
$1.15M |
| Avg Inst. Trade Volume: |
.18M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.6M |
| Avg Closing Trade (30 D): |
$3.44M |
| Avg Closing Trade (90 D): |
$3.44M |
| Avg Closing Volume: |
171.39K |
|
|
| Financials |
| |
TTM |
FY 2024 |
Q3 2024 |
|
Basic EPS
|
|
|
|
|
Diluted EPS
|
|
|
|
|
Revenue
|
$ 50.92M
|
$ 138.1M
|
$ 33.43M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ 23.53M
|
$ 31.87M
|
$ 5.74M
|
|
Operating Income / Loss
|
$ 22.62M
|
$ 25M
|
$ 4.11M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ M
|
$ 20.99M
|
$ -2.56M
|
|
PE Ratio
|
|
|
|
|
|
|
